Aktionsplan Kazia Therapeutics Limited
Erweiterter Zeitplan
Einfaches Diagramm
Über das Unternehmen Kazia Therapeutics Limited
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.| IPO date | 1999-01-06 |
|---|---|
| ISIN | US48669G1058 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | aud |
| Див.доход ао | 53.19 |
| Дивиденд ао | 4.09 |
| Сайт | https://www.kaziatherapeutics.com |
| Цена ао | 0.96 |
| Preisänderung pro Tag: | 0% (0.9952) |
|---|---|
| Preisänderung pro Woche: | +4.79% (0.9497) |
| Preisänderung pro Monat: | +5.91% (0.9397) |
| Preisänderung über 3 Monate: | -70.11% (3.33) |
| Preisänderung über sechs Monate: | +192.71% (0.34) |
| Preisänderung pro Jahr: | +290.43% (0.2549) |
| Preisänderung über 3 Jahre: | -83.55% (6.05) |
| Preisänderung über 5 Jahre: | -75.27% (4.0238) |
| Preisänderung über 10 Jahre: | 0% (0.9952) |
| Preisänderung seit Jahresbeginn: | -66.49% (2.97) |
|
|
Unterschätzung
|
Effizienz
|
|||||||||||||||||||||||||||||||||||||
Dividenden
|
Pflicht
|
Wachstumsimpuls
|
|||||||||||||||||||||||||||||||||||||
| Institutionen | Volumen | Aktie, % |
|---|---|---|
| Armistice Capital, LLC | 2475555 | 10.47 |
| Platinum Investment Management Ltd | 1821887 | 7.71 |
| Morgan Stanley | 201550 | 0.85 |
| Bank of Montreal/Can/ | 140166 | 0.59 |
| HSBC Holdings PLC | 100194 | 0.42 |
| TWO SIGMA SECURITIES, LLC | 58423 | 0.25 |
| XTX Topco Ltd | 19436 | 0.08 |
| Acadian Asset Management. LLC | 18682 | 0.08 |
| Citadel Advisors Llc | 12809 | 0.05 |
| BNP Paribas Financial Markets | 12700 | 0.05 |
| Aufsicht | Berufsbezeichnung | Zahlung | Geburtsjahr |
|---|---|---|---|
| Ms. Anna Sandham | Company Secretary | N/A | |
| Dr. John Edwin Friend II, M.D. | CEO, MD & Director | 731.09k | 1970 (55 Jahre) |
| Ms. Gabrielle Heaton BBUS (ACC), CPA | Principal Accounting Officer, VP of Finance & Administration and Principal Financial Officer | 178.56k |
Adresse: Australia, Sydney, Three International Towers - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.kaziatherapeutics.com
Webseite: https://www.kaziatherapeutics.com
